Multiple Dose Escalation Trial Of PF-04308515 In Healthy Volunteers

• Drug: PF-04308515
  
  PF-04308515 will be provided as an oral solution administered at doses of 3, 10, 30 and 100 mg. If an optional cohort is needed the dose would not exceed the established toxicokinetic exposure limits. Solution will be administered orally once daily for 14 days.
• Drug: Placebo
  
  Placebo solution will be administered to those volunteers who are randomized to the placebo arm. Placebo solution will be administered orally once daily for 14 days.
• Drug: PF-04308515 Tablet
  
  Tablet formulation to administer a 20 mg dose will be administered to volunteers in Part 2. The study medication will be administered orally once daily for 1 day.

• Experimental: (Part 1) PF-04308515
  
  Intervention: Drug: PF-04308515
• Placebo Comparator: (Part 1) Solution Placebo
  
  Intervention: Drug: Placebo
• Experimental: (Part 2) PF-04308515 Tablet
  
  Intervention: Drug: PF-04308515 Tablet

Inclusion Criteria:

• Healthy males between 18 and 55 years, inclusive
• Healthy females between 18 and 44 years, inclusive
• Females are required to be surgically sterile

Exclusion Criteria:

• Evidence or history of clinically significant disease
• Post-menopausal women
• History of intolerance or significant adverse effects with glucocorticoid therapy